Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse

Схожие документы

• Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
  по: Platzbecker, U, et al.
  Опубликовано: (2012)
• (18)F-FDG-PET/CT for detection of extramedullary acute myeloid leukemia
  по: Stölzel, Friedrich, et al.
  Опубликовано: (2011)
• Induction of short-term remission with single agent eltrombopag in refractory nucleophosmin-1-mutated acute myeloid leukemia
  по: Platzbecker, Uwe, et al.
  Опубликовано: (2014)
• Mobilization of PML/RARα negative peripheral blood stem cells with a combination of G-CSF and CXCR4 blockade in relapsed acute promyelocytic leukemia pre-treated with arsenic trioxide
  по: Stölzel, Friedrich, et al.
  Опубликовано: (2010)
• Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial
  по: Sockel, Katja, et al.
  Опубликовано: (2012)